GlassScriptPhysician profile
Raul Caldera, JR.
NPI 1104511500
$5,034.79
in general payments reported to CMS, 2019-2025
18 companies · $2,978 in 2025
The $2,978 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $284 · 2024: $1,773 · 2025: $2,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,951 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.79 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $2,007.42 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $696.73 | 2023-2025 | Ibsrela |
| Janssen Biotech, INC. | $472.38 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $453.55 | 2024-2025 | Vemlidy, Livdelzi |
| Phathom Pharmaceuticals, INC. | $372.16 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $326.47 | 2023-2025 | Sucraid, Sucraid |
| Abbvie INC. | $205.60 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $120.10 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $98.71 | 2025 | Vowst, Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.96 | 2024-2025 | Trulance, Xifaxan, Relistor |
| Boston Scientific Corporation | $50.42 | 2025 | Overstitch Endoscopic Suturing System |
| Ferring Pharmaceuticals INC. | $23.71 | 2025 | Rebyota |
| Merck Sharp & Dohme LLC | $23.17 | 2023 | Dificid |
| Albireo Pharma, INC. | $20.55 | 2024 | Iqirvo |
| Exact Sciences Corporation | $20.08 | 2024 | Cologuard Collection Kit |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pentax of America, INC. | $17.98 | 2023 | |
| Celltrion USA INC. | $14.23 | 2025 | Vegzelma |
| Novo Nordisk INC | $13.57 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Caldera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.